Immunovant (IMVT) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
9 Nov, 2026Strategic focus and platform
Anti-FcRn strategy targets autoantibody-driven diseases; the class had >$4.3B in global sales in 2025 and 20+ indications announced or in development.
IMVT-1402 is positioned for potential best-in-class IgG reduction, with deep, rapid, dose-dependent reductions and a simple autoinjector; efficacy and safety claims remain subject to clinical evaluation.
Current trials are expected to potentially address ~500K US patients across Graves’ disease, ACPA+ difficult-to-treat RA, MG and CIDP.
All current IMVT-1402 trials use the intended commercial YpsoMate autoinjector; at-home or HCP administration takes <10 seconds.
Clinical development and milestones
Potentially registrational trials are enrolling in Graves’ disease, MG and CIDP; the regulatory status depends on future FDA alignment on trial design, endpoints, statistical plans and development strategy.
Topline data are targeted for 2027 in Graves’ disease and MG, and 2028 in CIDP; ACPA+ D2T RA had positive Period 2 data.
In Graves’ disease, batoclimab responders included 17 of 21 assessed patients who remained responders six months off treatment; 8 of 17 responders were off all medication at Week 48.
In MG, Phase 3 batoclimab data showed a 5.6-point MG-ADL reduction with 680 mg and 42% minimal symptom expression; comparisons were cross-trial, not head-to-head.
In CIDP, batoclimab Phase 2b data showed an 84% alNCAT response rate among patients with ≥70% IgG reduction; results informed IMVT-1402 trial design.
Difficult-to-treat RA results
IMVT-1402 600 mg met the Period 2 primary endpoint: Week 28 ACR20 response was 92.5% with continued 600 mg versus 75.6% after switching to placebo (p=0.0139).
Week 28 ACR50 responses were 80.0% with continued 600 mg versus 56.1% with placebo (nominal p=0.0117); ACR70 responses were 52.5% versus 36.6% (nominal p=0.1674).
Period 2 treatment-emergent adverse events occurred in 22.5% of 600 mg recipients versus 30.8% with placebo; no Grade ≥3 events, serious events or discontinuations due to adverse events were reported in these arms.
FDA interaction was planned for later in 2026 to determine the path forward for the D2T RA program.
Latest events from Immunovant
- IMVT-1402 met the D2T RA primary endpoint; $722.3M cash supports the current plan.IMVT
Q2 2027 - IMVT-1402 targets major autoimmune diseases with best-in-class efficacy and broad market potential.IMVT
Corporate presentation - IMVT-1402 is poised to lead in autoimmune therapy with deep IgG reduction and broad clinical potential.IMVT
Roivant Investor Day presentation - Imminent brepocitinib DM launch and advancing IMVT-1402 trials drive a pivotal, cash-rich period.IMVT
Q1 2027 - IMVT-1402 targets major autoimmune diseases with best-in-class efficacy and broad clinical reach.IMVT
Corporate presentation - Virtual annual meeting to vote on directors, auditor, and executive pay, all board-recommended.IMVT
Proxy filing - Proxy covers director elections, auditor ratification, and executive pay, emphasizing governance.IMVT
Proxy filing - Five INDs cleared for IMVT-1402, with $472.9M cash and pivotal trials imminent.IMVT
Q2 2025 - IMVT-1402 achieved high response rates in uncontrolled Graves', with pivotal trial set for year-end.IMVT
Status Update